Redburn Atlantic Begins Coverage on Kenvue (NYSE:KVUE)

Redburn Atlantic began coverage on shares of Kenvue (NYSE:KVUE) in a research report sent to investors on Thursday morning, Marketbeat reports. The firm issued a neutral rating and a $23.50 target price on the stock.

Several other equities analysts have also weighed in on KVUE. Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.42.

Kenvue Stock Up 1.1 %

Shares of Kenvue stock opened at $22.10 on Thursday. The firm has a market cap of $42.25 billion, a price-to-earnings ratio of 41.71, a P/E/G ratio of 2.62 and a beta of 1.02. The stock has a 50-day simple moving average of $22.65 and a 200-day simple moving average of $22.40. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.71%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Institutional Trading of Kenvue

A number of hedge funds have recently modified their holdings of the company. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new stake in Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC lifted its stake in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Finally, Versant Capital Management Inc lifted its stake in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.